WO2009152095A3 - Nucleoside cyclicphosphates - Google Patents

Nucleoside cyclicphosphates Download PDF

Info

Publication number
WO2009152095A3
WO2009152095A3 PCT/US2009/046619 US2009046619W WO2009152095A3 WO 2009152095 A3 WO2009152095 A3 WO 2009152095A3 US 2009046619 W US2009046619 W US 2009046619W WO 2009152095 A3 WO2009152095 A3 WO 2009152095A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
cyclicphosphates
salts
solvates
stereoisomers
Prior art date
Application number
PCT/US2009/046619
Other languages
French (fr)
Other versions
WO2009152095A2 (en
Inventor
Jinfa Du
Dhanapalan Nagarathnam
Ganapati Reddy Pamulapati
Bruce S. Ross
Michael Joseph Sofia
Original Assignee
Pharmasset, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2009257647A priority Critical patent/AU2009257647C1/en
Priority to KR1020117000655A priority patent/KR101682494B1/en
Priority to KR1020167033252A priority patent/KR20160139060A/en
Priority to JP2011513609A priority patent/JP5749160B2/en
Priority to CN200980131006XA priority patent/CN102119167A/en
Priority to ES09763386.1T priority patent/ES2536727T3/en
Priority to EP09763386.1A priority patent/EP2313422B1/en
Priority to MX2010013768A priority patent/MX2010013768A/en
Application filed by Pharmasset, Inc. filed Critical Pharmasset, Inc.
Priority to CA2727495A priority patent/CA2727495C/en
Priority to BRPI0915484A priority patent/BRPI0915484A2/en
Publication of WO2009152095A2 publication Critical patent/WO2009152095A2/en
Publication of WO2009152095A3 publication Critical patent/WO2009152095A3/en
Priority to ZA2010/08829A priority patent/ZA201008829B/en
Priority to IL209916A priority patent/IL209916A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: Formula (I)
PCT/US2009/046619 2008-06-11 2009-06-08 Nucleoside cyclicphosphates WO2009152095A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP09763386.1A EP2313422B1 (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
KR1020167033252A KR20160139060A (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
JP2011513609A JP5749160B2 (en) 2008-06-11 2009-06-08 Nucleoside cyclic phosphate
CN200980131006XA CN102119167A (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
ES09763386.1T ES2536727T3 (en) 2008-06-11 2009-06-08 Nucleoside Cyclophosphates
AU2009257647A AU2009257647C1 (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
MX2010013768A MX2010013768A (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates.
KR1020117000655A KR101682494B1 (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
CA2727495A CA2727495C (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates
BRPI0915484A BRPI0915484A2 (en) 2008-06-11 2009-06-08 cyclic nucleoside phosphates
ZA2010/08829A ZA201008829B (en) 2008-06-11 2010-12-08 Nucleoside cyclicphosphates
IL209916A IL209916A (en) 2008-06-11 2010-12-09 Nucleoside cyclic phosphates and their use for treating viral disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6068308P 2008-06-11 2008-06-11
US61/060,683 2008-06-11
US14036908P 2008-12-23 2008-12-23
US61/140,369 2008-12-23
US12/479,075 2009-06-05
US12/479,075 US8173621B2 (en) 2008-06-11 2009-06-05 Nucleoside cyclicphosphates

Publications (2)

Publication Number Publication Date
WO2009152095A2 WO2009152095A2 (en) 2009-12-17
WO2009152095A3 true WO2009152095A3 (en) 2010-11-04

Family

ID=40974681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046619 WO2009152095A2 (en) 2008-06-11 2009-06-08 Nucleoside cyclicphosphates

Country Status (19)

Country Link
US (2) US8173621B2 (en)
EP (1) EP2313422B1 (en)
JP (2) JP5749160B2 (en)
KR (2) KR101682494B1 (en)
CN (1) CN102119167A (en)
AR (1) AR072104A1 (en)
AU (1) AU2009257647C1 (en)
BR (1) BRPI0915484A2 (en)
CA (1) CA2727495C (en)
CL (1) CL2010001407A1 (en)
CO (1) CO6321272A2 (en)
ES (1) ES2536727T3 (en)
IL (1) IL209916A (en)
MX (1) MX2010013768A (en)
PT (1) PT2313422E (en)
TW (1) TW201002733A (en)
UY (1) UY31892A (en)
WO (1) WO2009152095A2 (en)
ZA (1) ZA201008829B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
SI3521297T1 (en) 2003-05-30 2022-04-29 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
TW201031675A (en) * 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CN102421293A (en) * 2009-03-20 2012-04-18 艾丽奥斯生物制药有限公司 Substituted nucleoside and nucleotide analogs
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
US8940313B2 (en) 2010-04-23 2015-01-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
KR20130110170A (en) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. Substituted nucleotide analogs
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
EP2655392B1 (en) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
JP2014514295A (en) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド Compounds and pharmaceutical compositions for the treatment of viral infections
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
TW201329096A (en) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
DE202012013382U1 (en) 2011-09-16 2016-08-23 Gilead Pharmasset Llc Compositions for the treatment of HCV
US8507460B2 (en) * 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013090420A2 (en) * 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
RS56212B1 (en) 2011-12-20 2017-11-30 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
DK2794627T3 (en) 2011-12-22 2019-01-14 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX2014014323A (en) * 2012-05-25 2015-02-12 Janssen R & D Ireland Uracyl spirooxetane nucleosides.
AR091166A1 (en) * 2012-05-29 2015-01-14 Hoffmann La Roche PROCESS FOR OBTAINING NUCLEOSID COMPOUNDS 2-DESOXI-2-FLUOR-2-METHYL-D-RIBOFURANOSIL
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
TR201809048T4 (en) 2012-10-08 2018-07-23 Centre Nat Rech Scient 2'-chloro nucleoside analogs for HCV infection.
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
CN103804417B (en) * 2012-11-13 2017-09-19 北京美倍他药物研究有限公司 Anti-hepatic-B virus medicine
JP2016501200A (en) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 2-Alkynyl-substituted nucleoside derivatives for treating viral diseases
US20140205566A1 (en) * 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
ES2865402T3 (en) * 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleosides, 4'-fluoronucleotides and analogues thereof for the treatment of HCV
PT2950786T (en) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
WO2014186637A1 (en) 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
SI3650014T1 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA117375C2 (en) * 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3074412A4 (en) * 2013-11-28 2017-05-31 Janssen Sciences Ireland UC Crystal form of nucleoside inhibitor of hcv
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN106536538A (en) * 2014-04-24 2017-03-22 共晶制药股份有限公司 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016066283A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN104817599B (en) * 2015-03-20 2018-02-27 南京欧信医药技术有限公司 A kind of synthetic method of 5 hydroxyl tetrahydrofuran derivative
US10766917B2 (en) * 2015-05-27 2020-09-08 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
CN108026136A (en) 2015-08-06 2018-05-11 奇默里克斯公司 Pyrrolopyrimidine nucleosides as useful antivirotic and the like
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
MX2018014377A (en) 2016-05-27 2019-03-14 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors.
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PL3512863T3 (en) * 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
KR102335193B1 (en) 2017-02-01 2021-12-03 아테아 파마슈티컬즈, 인크. Nucleotide hemi-sulfate salts for treating hepatitis C virus
CN106810515A (en) * 2017-02-06 2017-06-09 抚州市星辰药业有限公司 The midbody compound and its synthetic method of a kind of synthesis Suo Feibuwei
KR20200056420A (en) 2017-09-21 2020-05-22 리보사이언스 엘엘씨 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
EP3684771A1 (en) 2017-09-21 2020-07-29 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF
CN109956975B (en) 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 Liver delivery entecavir prodrug nucleoside cyclic phosphate ester compound and application thereof
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
KR20200140865A (en) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. Treatment of HCV-infected patients with cirrhosis
US20220220145A1 (en) * 2019-04-22 2022-07-14 Ligand Pharmaceuticals, Inc. Cyclic phosphate compounds
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111253454B (en) * 2020-03-19 2022-03-08 江苏工程职业技术学院 Preparation method of anti-hepatitis C drug sofosbuvir
CN115605493A (en) 2020-03-20 2023-01-13 吉利德科学公司（Us） Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same
CN115605492A (en) 2020-04-21 2023-01-13 配体制药股份有限公司（Us） Nucleotide prodrug compounds
EP4232456A1 (en) * 2020-10-21 2023-08-30 Ligand Pharmaceuticals, Inc. Antiviral prodrug compounds
AU2022256476A1 (en) 2021-04-16 2023-10-12 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852267A (en) * 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
JPH05238939A (en) * 1992-02-27 1993-09-17 Noda Sangyo Kagaku Kenkyusho Hepatitis-treating agent
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
WO2005082144A1 (en) * 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Methylation inhibitor compounds
CN101108870A (en) * 2007-08-03 2008-01-23 冷一欣 Process for preparation of nucleoside phosphoric acid ester compound and application thereof

Family Cites Families (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
US2563707A (en) 1947-12-12 1951-08-07 American Cyanamid Co Process for preparing pteridines
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US3053865A (en) 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3097137A (en) 1960-05-19 1963-07-09 Canadian Patents Dev Vincaleukoblastine
US3104246A (en) 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
FR1533151A (en) 1962-05-18 1968-07-19 Rhone Poulenc Sa New antibiotic and its preparation
US3300479A (en) * 1965-08-05 1967-01-24 Upjohn Co Deazapurine riboside cyclic 3', 5'-phosphates and process therefor
US3376380A (en) * 1965-09-15 1968-04-02 Sylvania Electric Prod Synchronous demodulator with stabilized amplifiers and blanking
NL6613143A (en) 1965-09-21 1967-03-22
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
CH514578A (en) 1968-02-27 1971-10-31 Sandoz Ag Process for the production of glucosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3849397A (en) 1971-08-04 1974-11-19 Int Chem & Nuclear Corp 3',5'-cyclic monophosphate nucleosides
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
BE799805A (en) 1973-05-23 1973-11-21 Toyo Jozo Kk NEW IMMUNOSUPPRESSOR AND ITS PREPARATION
US3991045A (en) 1973-05-30 1976-11-09 Asahi Kasei Kogyo Kabushiki Kaisha N4 -acylarabinonucleosides
JPS535678B2 (en) 1973-05-30 1978-03-01
US3888843A (en) 1973-06-12 1975-06-10 Toyo Jozo Kk 4-carbamoyl-1-' -d-ribofuranosylimidazolium-5-olate
SU508076A1 (en) 1973-07-05 1976-10-05 Институт По Изысканию Новых Антибиотиков Амн Ссср Method for preparing carminomycin 1
GB1457632A (en) 1974-03-22 1976-12-08 Farmaceutici Italia Adriamycins
US3923785A (en) 1974-04-22 1975-12-02 Parke Davis & Co (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
GB1509875A (en) 1976-06-14 1978-05-04 Farmaceutici Italia Optically active anthracyclinones and anthracycline glycosides
SE445996B (en) 1977-08-15 1986-08-04 American Cyanamid Co NEW ATRAKINO DERIVATIVES
US4197249A (en) 1977-08-15 1980-04-08 American Cyanamid Company 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
US4203898A (en) 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4210745A (en) 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4303785A (en) 1978-08-05 1981-12-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Antitumor anthracycline antibiotics
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
DK160616C (en) 1979-02-03 1991-09-02 Zaidan Hojin Biseibutsu PROCEDURE FOR PREPARING ANTHRACYCLINE DERIVATIVES OR ACID ADDITIONAL SALTS THEREOF
JPS57109799A (en) * 1980-12-26 1982-07-08 Kikkoman Corp Novel 2-halogeno-adenosine-3',5'-cyclic alkyl triphosphate, its preparation and antitumor agent containing the same
NZ200204A (en) 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4355032B2 (en) 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
JPS5976099A (en) 1982-10-22 1984-04-28 Sumitomo Chem Co Ltd Aminonaphthacene derivative and its preparation
IT1155446B (en) 1982-12-23 1987-01-28 Erba Farmitalia PROCEDURE FOR THE PURIFICATION OF ANTHRACYCLINONIC GLUCOSIDES BY SELECTIVE ADSOBMENT ON RESINS
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
DE3485225D1 (en) 1983-08-18 1991-12-05 Beecham Group Plc ANTIVIRAL GUANINE DERIVATIVES.
JPS6051189A (en) 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US4760137A (en) 1984-08-06 1988-07-26 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
NL8403224A (en) 1984-10-24 1986-05-16 Oce Andeno Bv DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
DK173350B1 (en) 1985-02-26 2000-08-07 Sankyo Co Thiazolidine derivatives, their preparation and pharmaceutical composition containing them
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
DE3689976T2 (en) 1985-05-15 1995-03-16 Wellcome Found Therapeutic nucleosides and their production.
US5246937A (en) 1985-09-18 1993-09-21 Beecham Group P.L.C. Purine derivatives
US4751221A (en) 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
ZA898834B (en) * 1988-11-21 1990-08-29 Syntex Inc Antiviral agents
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5277914A (en) 1989-03-31 1994-01-11 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5041246A (en) 1990-03-26 1991-08-20 The Babcock & Wilcox Company Two stage variable annulus spray attemperator method and apparatus
JPH05506230A (en) 1990-04-06 1993-09-16 ジーンラブス　テクノロジイズ　インコーポレイテッド Hepatitis C virus epitope
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DK0527736T3 (en) 1990-05-18 1997-10-20 Hoechst Ag Isoxazole-4-carboxylic acid amides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and the use of these drugs.
US6060080A (en) 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
JP2599492B2 (en) 1990-08-21 1997-04-09 第一製薬株式会社 Manufacturing method of liposome preparation
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
JP3008226B2 (en) 1991-01-16 2000-02-14 第一製薬株式会社 Hexacyclic compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
HU9202318D0 (en) 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
TW224053B (en) 1991-09-13 1994-05-21 Paul B Chretien
DE4200821A1 (en) 1992-01-15 1993-07-22 Bayer Ag TASTE-MASKED PHARMACEUTICAL AGENTS
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5405598A (en) 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
CA2098887C (en) 1992-06-22 2003-10-28 Ta-Sen Chou Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2,2-difluoro-d-ribofuranosyl derivatives
US5256798A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL106840A (en) 1992-09-01 1998-09-24 Lilly Co Eli Process for basic anomerization of pentofuranosyl nucleosides
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
CN1078478C (en) 1993-02-24 2002-01-30 王瑞駪 Compositions and methods of application of reactive antiviral polymers
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
CA2167537A1 (en) 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
FR2707988B1 (en) 1993-07-21 1995-10-13 Pf Medicament New antimitotic derivatives of binary alkaloids of catharantus rosesus, process for their preparation and pharmaceutical compositions comprising them.
US7375198B2 (en) 1993-10-26 2008-05-20 Affymetrix, Inc. Modified nucleic acid probes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
ATE214940T1 (en) 1993-11-10 2002-04-15 Enzon Inc IMPROVED INTERFERON-POLYMER CONJUGATES
DE4447588C2 (en) 1994-05-03 1997-11-20 Omer Osama Dr Dr Med Treatment of herpes and hepatitis virus infections and bronchitis
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU710074B2 (en) 1994-06-22 1999-09-16 Proligo Llc Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
DE4432623A1 (en) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Process for bleaching aqueous surfactant solutions
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
GB9618952D0 (en) 1996-09-11 1996-10-23 Sandoz Ltd Process
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
EP0914421A2 (en) 1996-02-29 1999-05-12 Immusol, Inc. Hepatitis c virus ribozymes
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
PL185932B1 (en) * 1996-10-04 2003-09-30 Du Pont Polyester fibre
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
SK284054B6 (en) 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6455690B1 (en) 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
BR9714349A (en) 1996-10-16 2000-11-14 Icn Pharmaceuticals Purine L-nucleosides, their analogues and their uses
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US20020127371A1 (en) 2001-03-06 2002-09-12 Weder Donald E. Decorative elements provided with a circular or crimped configuration at point of sale or point of use
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
FR2765191B1 (en) * 1997-06-26 1999-08-20 Cermex METHOD AND MACHINE FOR AUTOMATICALLY BONDING A HEAT SHRINKABLE PLASTIC FILM ON THE BOTTOM OF AN OPEN BODY
EP1009732B1 (en) 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
JP3773148B2 (en) * 1997-10-29 2006-05-10 キッコーマン株式会社 Ischemic disease prevention, treatment and organ preservative
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
CN1192102C (en) 1998-01-23 2005-03-09 新生物生物公司 Enzyme catalyzed therapeutic agents
DE69933860T2 (en) 1998-02-25 2007-05-31 Emory University 2'-FLUORONUKLEOSIDE
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6653455B1 (en) 1998-10-16 2003-11-25 Mercian Corporation Crystallization of doxorubicin hydrochloride
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CN1079473C (en) 1999-05-31 2002-02-20 李岭群 Coupling rib for pre-fabricated beam
WO2001005433A2 (en) 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
EP1232166A2 (en) 1999-11-12 2002-08-21 Pharmasset Limited Synthesis of 2'-deoxy-l-nucleosides
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR20080021797A (en) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treating flaviviruses and pestiviruses
FR2810322B1 (en) 2000-06-14 2006-11-10 Pasteur Institut COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP)
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
NZ536942A (en) 2000-07-21 2006-03-31 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
AR039558A1 (en) 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002243791B2 (en) 2001-01-22 2006-06-29 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
NZ530000A (en) 2001-07-11 2007-03-30 Vertex Pharma Peptidomimetic bridged bicyclic serine protease inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
WO2003022861A1 (en) 2001-09-13 2003-03-20 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
GB0129945D0 (en) 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
US7105527B2 (en) 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
JP2005514401A (en) 2001-12-21 2005-05-19 マイクロロジックス　バイオテック，インコーポレイテッド Antiviral 7-deaza L-nucleoside
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US7070801B2 (en) 2002-01-30 2006-07-04 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AU2003209045B2 (en) 2002-02-13 2006-12-14 Isis Pharmaceuticals, Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management Nucleotide mimics and their prodrugs
BR0309557A (en) 2002-04-26 2005-03-01 Gilead Sciences Inc Non-Nucleoside Reverse Transcriptase Inhibitors
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
MXPA04012245A (en) 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents.
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0305258A (en) 2002-07-01 2004-10-05 Upjohn Co Hcv ns5b polymerase inhibitors
WO2004002977A1 (en) 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
US7323449B2 (en) 2002-07-24 2008-01-29 Merck & Co., Inc. Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2004011478A2 (en) 2002-07-25 2004-02-05 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
US7186700B2 (en) 2002-09-13 2007-03-06 Idenix Pharmaceuticals, Inc. β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
EP1554271A1 (en) 2002-10-15 2005-07-20 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP4537315B2 (en) 2002-11-01 2010-09-01 バイロファーマ・インコーポレイテッド Benzofuran compounds, compositions and methods for treating or preventing hepatitis C infection and related diseases
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004052899A2 (en) 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
DE602004014470D1 (en) 2003-01-14 2008-07-31 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
EP1745573A4 (en) 2003-03-20 2010-05-26 Microbiol Quimica Farmaceutica Methods of manufacture of 2 -deoxy- beta-l-nucleosides
US20040202993A1 (en) 2003-04-10 2004-10-14 Poo Ramon E. Apparatus and method for organ preservation and transportation
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
DK1628685T3 (en) 2003-04-25 2011-03-21 Gilead Sciences Inc Antiviral phosphonate analogues
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
SI3521297T1 (en) 2003-05-30 2022-04-29 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE602004028841D1 (en) 2003-07-25 2010-10-07 Centre Nat Rech Scient PURIN NUCLEOSIDE FOR THE TREATMENT OF FLAVIVIDRAIC DISEASES, INCLUDING HEPATITIS C
RU2006109491A (en) 2003-08-27 2006-08-10 Байота, Инк. (Au) NEW TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS A THERAPEUTIC MEDICINES
TW200526686A (en) 2003-09-18 2005-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
CN100384237C (en) 2004-02-28 2008-04-23 鸿富锦精密工业（深圳）有限公司 Volume adjustment set and method
US8759317B2 (en) 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
GB0408995D0 (en) 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
WO2006000922A2 (en) 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CA2571079A1 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7217523B2 (en) 2004-07-02 2007-05-15 Regents Of The University Of Minnesota Nucleoside phosphoramidates and nucleoside phosphoramidases
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
CN101027062A (en) 2004-07-27 2007-08-29 吉里德科学公司 Phosphonate analogs of HIV inhibitor compounds
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
DE602005015466D1 (en) 2004-08-23 2009-08-27 Hoffmann La Roche ANTIVIRAL 4'-AZIDONUCLEOSIDE
CN101048403B (en) 2004-08-23 2010-06-16 弗·哈夫曼-拉罗切有限公司 Heterocyclic antiviral compounds
ES2725457T3 (en) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
WO2006035061A1 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
KR20070100237A (en) 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Therapeutic furopyrimidines and thienopyrimidines
JP2008523082A (en) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Nucleotides having antibacterial and anticancer activities
GB0427123D0 (en) 2004-12-11 2005-01-12 Apv Systems Ltd Food item coating apparatus and method
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
CN101128474A (en) 2005-02-28 2008-02-20 健亚生物科技公司 Tricyclic-nucleoside prodrugs for treating viral infections
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006119347A1 (en) 2005-05-02 2006-11-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
JP2009502969A (en) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド Amorphous efavirenz and its manufacture
DE602006019883D1 (en) 2005-07-29 2011-03-10 Medivir Ab MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
DK1912996T3 (en) 2005-07-29 2012-09-17 Janssen R & D Ireland Macrocyclic inhibitors of hepatitis C virus
WO2007013047A2 (en) 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
PL1912997T3 (en) 2005-07-29 2012-02-29 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
US8012939B2 (en) 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
JP2009504704A (en) 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Antiviral 4'-substituted pronucleotide phosphoramidate
GB0519478D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2007065829A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Antiviral nucleosides
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
JP2009526850A (en) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Nucleoside aryl phosphoramidates for treating RNA-dependent RNA viral infections
EP1987030B1 (en) 2006-02-17 2011-11-09 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2343914T3 (en) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company INDOLOBENZAZEPIN HCV NS5B INHIBITORS CONDENSED WITH CYCLOPROPYL.
EP2043613A1 (en) 2006-07-14 2009-04-08 Fmc Corporation Solid form
EP1881001A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
WO2008045419A1 (en) 2006-10-10 2008-04-17 Pharmasset, Inc. Preparation of nucleosides ribofuranosyl pyrimidines
PL216525B1 (en) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
EP2136626A4 (en) 2007-03-19 2011-02-23 Oregon State Mannich base n-oxide drugs
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN100532388C (en) 2007-07-16 2009-08-26 郑州大学 2'-fluorine-4'-substituted-nucleosides analog, preparation method and uses thereof
US20100256098A1 (en) 2007-08-31 2010-10-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP5238939B2 (en) 2007-11-07 2013-07-17 三菱化学株式会社 Long fiber reinforced composite resin composition and molded product
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2009142822A2 (en) 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
RS57092B1 (en) 2008-04-23 2018-06-29 Gilead Sciences Inc 1' -substituted carba-nucleoside analogs for antiviral treatment
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
ES2435799T3 (en) 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis C virus by combining a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
WO2010080878A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Combination of a cyclosporine derivative and nucleosides for treating hcv
JO3027B1 (en) 2009-05-14 2016-09-05 Janssen Products Lp Uracyl Spirooxetane Nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8719767B2 (en) 2011-03-31 2014-05-06 Commvault Systems, Inc. Utilizing snapshots to provide builds to developer computing devices
BR122021021135B1 (en) 2009-09-21 2022-08-30 Gilead Sciences, Inc 2-FLUORINE SUBSTITUTED CARBA-NUCLEOSIDE ANALOG COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF CARBONUCLEOSID 2'-FLUORINE SUBSTITUTED ANALOG COMPOUNDS
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852267A (en) * 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
JPH05238939A (en) * 1992-02-27 1993-09-17 Noda Sangyo Kagaku Kenkyusho Hepatitis-treating agent
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
WO2005082144A1 (en) * 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Methylation inhibitor compounds
CN101108870A (en) * 2007-08-03 2008-01-23 冷一欣 Process for preparation of nucleoside phosphoric acid ester compound and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BASCHANG, GERHARD ET AL: "New derivatives of thymidine 3',5'-cyclophosphate", ANGEWANDTE CHEMIE , 85(1), 44 -5 CODEN: ANCEAD; ISSN: 0044-8249, 1973, XP002599755 *
BROEDERS, NIEK L. H. L. ET AL: "A 400- and 600-MHz proton NMR conformational study on nucleoside cyclic 3',5' Pv-TBP systems. Conformational transmission induces diequatorial orientation of the 3',5'-dioxaphosphorinane ring in a nonchair conformation", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 112(21), 7475 82 CODEN: JACSAT; ISSN: 0002-7863, 1990, XP002599754 *
ENGELS, JOACHIM ET AL: "Cyclophosphates. III. Synthesis and properties of uridine 3',5'-cyclophosphate esters", CHEMISCHE BERICHTE , 110(6), 2019 -27 CODEN: CHBEAM; ISSN: 0009-2940, 1977, XP002599753 *
NELSON K A ET AL: "THE QUESTION OF CHAIR-TWIST EQUILIBRIA FOR THE PHOSPHATE RINGS OF NUCLEOSIDE CYCLIC 3' 5' MONOPHOSPHATES PROTON NMR AND X-RAY CRYSTALLOGRAPHIC STUDY OF THE DIASTEREOMERS OF THYMIDINE PHENYL CYCLIC 3' 5' MONOPHOSPHATE", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 109, no. 13, 1987, pages 4058 - 4064, XP002599752, ISSN: 0002-7863 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs

Also Published As

Publication number Publication date
EP2313422A2 (en) 2011-04-27
AU2009257647C1 (en) 2014-10-23
AU2009257647A1 (en) 2009-12-17
JP2015180655A (en) 2015-10-15
KR20110016501A (en) 2011-02-17
KR20160139060A (en) 2016-12-06
IL209916A0 (en) 2011-02-28
US20120258928A1 (en) 2012-10-11
CN102119167A (en) 2011-07-06
PT2313422E (en) 2015-06-05
CA2727495A1 (en) 2009-12-17
BRPI0915484A2 (en) 2019-09-17
CL2010001407A1 (en) 2011-05-06
US20100081628A1 (en) 2010-04-01
MX2010013768A (en) 2011-03-03
AU2009257647B2 (en) 2014-04-10
EP2313422B1 (en) 2015-03-04
US8173621B2 (en) 2012-05-08
JP2011524356A (en) 2011-09-01
ES2536727T3 (en) 2015-05-28
AR072104A1 (en) 2010-08-04
ZA201008829B (en) 2011-09-28
UY31892A (en) 2010-01-05
JP5749160B2 (en) 2015-07-15
US8759510B2 (en) 2014-06-24
CO6321272A2 (en) 2011-09-20
CA2727495C (en) 2017-08-29
TW201002733A (en) 2010-01-16
KR101682494B1 (en) 2016-12-05
WO2009152095A2 (en) 2009-12-17
IL209916A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
WO2009152095A3 (en) Nucleoside cyclicphosphates
PH12014502771A1 (en) Nucleoside phosphoramidate prodrugs
AR121612A2 (en) GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
NZ593647A (en) Synthesis of purine nucleosides
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
PE20120495A1 (en) ETHYL 3-CYCLOPENTILAMINO-2,2-DIFLUOR-PROPANOATE AS AN INTERMEDIARY IN THE PREPARATION OF PYRIMIDODIAZEPINES
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
TN2009000024A1 (en) Prodrug of cinnamide compound
RS53292B (en) Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
EA201270216A1 (en) PHARMACEUTICAL COMPOSITION
NO20091858L (en) Hydrobenzamide derivatives as inhibitors of HSP90
MX2009007260A (en) Cyclized derivatives as eg-5 inhibitors.
JO3067B1 (en) Pyrazolylaminopyridines as inhibitors of fak
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
WO2011076784A3 (en) New inhibitors of cyclophilins and uses thereof
MX2011009898A (en) Process for the preparation of propionic acid derivatives.
MX359363B (en) DIHYDROETORPHINES and THEIR PREPARATION.
EA201270302A1 (en) ANHARROUND FORMS OF PYRIDINE DERIVATIVES
MX2010009926A (en) New process for the preparatiion of cyclohexanecarboxylic acid dericatives.
MX2010009876A (en) New process for the preparation of cyclohexanecarboxylic acid derivatives via the corresponding cyclohexanecarboxamide derivative.
WO2008141097A9 (en) Stereoisomers propofol therapeutic compounds
WO2011037985A8 (en) Aminothienopyridazine inhibitors of tau assembly
CY1111873T1 (en) NEW METHOD OF RECOGNIZING CRYSTALLIC FORM V OF AGOMELATIN
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980131006.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763386

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 589838

Country of ref document: NZ

Ref document number: 209916

Country of ref document: IL

Ref document number: 2727495

Country of ref document: CA

Ref document number: 12010502775

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011513609

Country of ref document: JP

Ref document number: MX/A/2010/013768

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009257647

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10164099

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2009763386

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117000655

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010150673

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009257647

Country of ref document: AU

Date of ref document: 20090608

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0915484

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101213